Latest Equities News

Page 229 of 399
Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.
Victor Sage
Victor Sage
29 Aug 2025
Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.
Victor Sage
Victor Sage
29 Aug 2025
Vinyl Group Ltd reports a striking 190% revenue increase in FY25, driven by acquisitions and organic growth, while preparing for its first EBITDA positive quarter by December 2025.
Victor Sage
Victor Sage
29 Aug 2025
Pengana Private Equity Trust reported a robust FY25 with a 7.6% NAV increase and a strong net profit of $50 million, underpinned by a diversified global private equity portfolio and a strategic buyback program.
Victor Sage
Victor Sage
29 Aug 2025
Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.
Ada Torres
Ada Torres
29 Aug 2025
DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.
Claire Turing
Claire Turing
29 Aug 2025
Bridge SaaS Limited reported a remarkable 524.6% revenue jump to $7.47 million for FY25, driven by its acquisition of Brightside Disability Support & Respite. Despite this growth, the company narrowed its loss to $1.13 million but remains unprofitable.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.
Ada Torres
Ada Torres
29 Aug 2025
First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.
Ada Torres
Ada Torres
29 Aug 2025
Victor Group Holdings has sharply reduced its FY25 loss to $275,449 from $3.53 million the prior year, while expanding its fintech presence through strategic stakes in LIT Technology and iRich Finance.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.
Ada Torres
Ada Torres
29 Aug 2025